Dizen Pharmaceuticals (688192.SH): There is uncertainty about whether the authorization license agreement signed with AstraZeneca can take effect.

Wisdom Financial News APP announced that Dize Pharmaceutical (688192.SH) has issued a stock price abnormal movement announcement, stating that the company has recently signed a licensing agreement with AstraZeneca UK Limited ("AstraZeneca") to grant AstraZeneca the exclusive rights to develop and commercialize Xuewozhe globally. As of the announcement disclosure date, the above-mentioned transaction still needs to be submitted to the company's shareholder meeting for approval. The final effectiveness is subject to meeting customary closing conditions and obtaining necessary approvals from overseas antitrust regulators and other relevant authorities. There is uncertainty as to whether the licensing agreement will come into effect.